
Financial markets trader/investor π #vaccineinjured w/ #POTS which onset after my Pfizer Covid vaccine #NEISvoidπ¦π₯
somewhere in the USA
Joined August 2020
- Tweets19.2K
- Following2.1K
- Followers1.4K
- Likes61.1K
What many may fail to recognize as a harm of the campaign to discredit the #vaccineinjured is that it will make it even harder for us to get meaningful help, both medical and financial.
You are not just hurting our feelings; you are threatening our survival. (1)
R. Anne Teaze π₯π¦ ποΈ retweeted
$ES - low yesterday was yearly VWAP.
Crazy market. That bounce of the low in SPX and back to the open looks hopeful. If it holds, it is back over the 200 day. (I hope I didn't speak too soon.)
1
35
I fully agree with this. Those NIH trials were designed to fail. So either all these experts are stupid or it is intentional. So disgusting.
The Regeneron POTS trial shows why almost all Long COVID treatment trials fail: It's their design. This is why I'm so confident that the Tirzepatide and SGB trials will fail, and why I honestly don't believe they're being run with good intentions:
31
R. Anne Teaze π₯π¦ ποΈ retweeted
Sigh. So frustrating. Makes me take a deep breath this morning and remember why our collaborative work matters.
These study results indicate that "Gamunex-C, a form of intravenous immunoglobulin (IVIG) that contains antibodies to help the body protect itself against infection from various diseases, does not have a significant impact on symptoms of severe postural orthostatic tachycardia syndrome (POTS) following COVID-19, according to results from the clinical trial RECOVER-AUTONOMIC (IVIG)."
This raises serious questions about clinical trial design. In an effort to move quickly and at scale, we continue to study broad groups of patients who share a diagnosis but may have very different underlying biological mechanisms.
We cannot continue treating patients with complex chronic illnesses as a homogeneous group simply because they share a diagnosis. These conditions are biologically heterogeneous, and trials must reflect that. Every trial should incorporate a strategy for patient subtyping, even when validated biomarkers are not yet available. Otherwise, we risk missing meaningful treatment responses in specific patient populations and dismissing potentially effective therapies.
So, what HAVE we learned? This study has uncovered important insights. And that matters. We cannot throw up our hands when we encounter obstacles or a tough headline.
β It's NOT that IVIG is ineffective for all patients. This trial does not establish that. It simply showed that IVIG did not demonstrate an overall benefit in the population studied, broadly defined by post-COVID POTS.
β A shared diagnosis does not necessarily mean shared underlying biology or a shared response to treatment.
β These critical questions remains: Are there biologically defined subgroups that could benefit from IVIG, how do we identify them and how must we design trials capable of studying them?
We need to examine the results, understand what they tell us, identify what remains unanswered, and use that knowledge to design better studies. Every study gives us something to build on, including this one, despite its outcome.
recovercovid.org/news/latestβ¦
I am active in several POTS communities online and when I hear others talk about their illnesses, I become so aware about how different we all are. It is crazy they lump us together for studies.
Bin gespannt wie die Einschlusskriterien waren.
Weil wenn nicht nach zumindest plausibler AutoimmunitΓ€t gescreent wurde, wΓ€re das Ergebnis wenig ΓΌberraschend.
1/3
35
If they don't carefully select the subset of patients most likely to benefit this is what happens. Phase 2 should be where we discover who that group is. Did they even design the trial so we could discover that? OMG.
1
2
147
Hmmm. Regeneron. I didn't even know they were trialing a drug for POTS
Regeneronβs Phase 2 trial in 82 POTS patients found that a single dose of baloncibart reduced standing heart rate by 11.4 bpm versus placebo and improved symptoms.
The antibody blocks NPR1, with biomarkers suggesting increased blood volume.
investor.regeneron.com/news-β¦
1
91
Bought the dip, sold the rip. It's too soon to invest in this market. It's a trader's market and likely has some more downside in the coming months.
1
36
R. Anne Teaze π₯π¦ ποΈ retweeted
Another lovely review, so glad Ekin is happy with the service! She was my first client from her country too!
If you want help understanding "gifts" chronic illness brings like ME, POTS, MCAS, hydration, blood sugar issues, etc, you can book here: lc-sc.co.uk/book-an-appointmβ¦

ALT 5 star review reading: Harriet was absolutely amazing. The consultation was so helpful for me, more helpful than any of the doctors I have been to. She is generous with her knowledge and her time. I wholeheartedly recommend booking a session with her in order to gain a better understanding of your complex symptoms. 100 % happy with her service ~Ekin Ghandour
R. Anne Teaze π₯π¦ ποΈ retweeted
Great article primarily about @LBatemanMD's hard work spanning over decades, but also with @RobWust and the work of @VirusesImmunity and @PutrinoLab.
archive.today/sVXML
#pwme #myalgicE #millionsmissing #severeME #LongCovid
Democratic socialists get the attention, but moderates made this week's Democratic majorities. They delivered lion's share of House flips and vastly outperformed Bernie Sanders' Senate candidates. That & more in today's newsletter: wsj.com/politics/elections/aβ¦
Hinojosa is a pragmatist who just wants fairness for her constitutients and the market acted like she was the reincarnation of Chairman Mao.
Am I crazy to think that if Texas Gov.-elect Gina Hinojosa were against the data center buildout, she wouldn't be saying I DO NOT HATE DATA CENTERS?
Tech companies just need to pay the vig to communities to build. That's not a big deal.
1
1
77
R. Anne Teaze π₯π¦ ποΈ retweeted
On days like today, diversification matters. Beer, whisky, vodka, wine and tequila have all helped me forget about my portfolio.

















